Invesco DB Oil Fund vs Ginkgo Bioworks Holdings Inc — how do they compare? Invesco DB Oil Fund trades at $23.56 (market cap $255.13M), while Ginkgo Bioworks Holdings Inc trades at $11.99 (market cap $763.64M). The key difference: Ginkgo Bioworks Holdings Inc is far larger — about 3× Invesco DB Oil Fund's market cap, and Invesco DB Oil Fund is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Oil Fund for 31 Days and Ginkgo Bioworks Holdings Inc for 7 Days on average.
| DBO | DNA | |
|---|---|---|
Market Cap | $255.13M | $763.64M |
Volume | 562,167 | 3,204,177 |
Sector | Commodities - Energy | Health |
52-Week High | $26.35 | $15.83 |
52-Week Low | $11.98 | $5.48 |
Typical Hold Time | 31 Days | 7 Days |
Enterprise Value | — | $865.59M |
Signals from Pluang's Aura AI — not financial advice
DBO trades at $23.54, down 0.42% on the day, with technical indicators showing a neutral to bearish bias. The stock faces resistance at $24 and support at $23, while moving averages signal bearish momentum. Recent oil market developments, including Middle East tensions and OPEC+ production decisions, create a volatile backdrop for energy stocks.
The outlook remains cautious given geopolitical risks and mixed oil price signals. Investment opportunities exist if supply disruptions persist, but risks include potential price declines from strategic reserve releases and ongoing legal challenges facing the oil industry.
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.
The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →